Sunshine Nohe and YiMiao ShenZhou's ZM001 for Systemic Lupus Erythematosus Enters Phase I Clinical Trial

(Source: Caiwen)

According to industry practice, high-value cell therapies usually advance the layout of commercial insurance and innovative payment solutions. While the company collaborates with Beijing Yimiaoshenzhou Medical Techology Co., Ltd. on advancing the R&D process of the pipeline, it will also comprehensively consider future commercialization pathways.

There are investors whoSunNovo（688621.SH）Question: The company's ZM001 (Systemic Lupus Erythematosus) has entered Phase I clinical trials, with the potential for a "one-shot cure." Considering the high cost of cell therapy, what are the company's plans for commercial pricing and patient accessibility in the future? Will it consider collaborating with medical insurance or commercial insurance institutions in advance?

On April 3, the company responded that ZM001 is currently in Phase I clinical trials. The company will distribute profits with its partner, Beijing Yimiaoshenzhou Medical Technology Co., Ltd., according to the agreed ratio. Referring to industry practices, high-value cell therapies are usually planned in advance for commercial insurance and innovative payment solutions. While jointly advancing the R&D process, the company and Beijing Yimiaoshenzhou Medical Technology Co., Ltd. will comprehensively consider future commercialization pathways.